Market Research Store

By 2020, Depression Drug Market Will Hit $11.3 Bn

Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2014 – 2020

 

Deerfield Beach, FL -- (SBWIRE) -- 02/13/2017 -- Zion Research has published a new report titled "Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020" According to the report, the global depression drug market was valued at USD 14.51 billion in 2014 and is expected to generate revenue of USD 16.8 billion by end of 2020, growing at a CAGR of 2.50% between 2015 and 2020.

Request Sample Report: http://bit.ly/1pwZCta

Depression is a medical disorder that mainly involves brain. Individual with depression feel sad, tired, lack energy, and have intricacy enjoying routine activities every day. It is a very common condition that affects about 1 in every 5 individual in the U.S. Many factors can cause depression, including genes, factors such as stress and brain chemistry. According to WHO (world health organization and center for disease control) at present an estimated 350 million people worldwide are affected with depression.

Some of the key reasons driving depression drug market are growing geriatric population, rising efficacy and declining side effects of drugs in numerous classes. Nevertheless, present circumstances specifies that the overall depression drug market would decline owing to patent expiry of main antidepressants, rising number of generic drug variants and weak pipeline of new drugs.

Browse the full "Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2014 – 2020" report at http://www.marketresearchstore.com/report/depression-drug-market-z53043

Different types of depression also have dissimilar symptoms. Several types of depression disorders include postpartum depression, major or clinical depressive disorder, dysthymic disorder, psychotic depression and seasonal affective disorder. Different classes of depression drugs are anticonvulsants, serotonin-norepinephrine reuptake inhibitors, beta-blockers, benzodiazepines, tetracyclic antidepressants (TeCAs), selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs) among others. Among all classes, SNRIs emerged as budding segment in 2014 and held more than 32% of the overall market share. However, it is predicted that this segment may exhibit decline in growth in the near future.

Geographically, North America emerged as major regional market for the global depression drug in 2014. This dominance was mainly because of presence of large population infected with numerous kinds of depression and anxiety disorders. Currently, U.S. is saturated as a variety of antidepressant drugs are available on prescription for the similar symptom. Depression drug market growth heavily relies on introduction of more efficient drugs for latest symptoms. Asia Pacific is predicted to show moderate growth due to presence of emerging economies such as Japan, Australia and China. Growth in this region is attributed to different factors such as positive marketing approval for novel medicines, presence of a large population base in the region and increasing geriatric population.

Do Inquiry before buying: http://bit.ly/2dfYMPN

Major companies operating in this field are H. Lundbeck, Opko Health, Gedeon Richter, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Abbott Laboratories, Novartis, Otsuka Pharmaceutical and SK Biopharmaceuticals among others.

This report segments the global depression drug market as follows:

Global Depression Drug Market: Class Segment Analysis

Atypical Antipsychotics
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Tetracyclic Antidepressants
Monoamine Oxidase inhibitors
Benzodiazepines
Others
Global Depression Drug Market: Regional Segment Analysis

North America
U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa

Contact US:

Joel John
3422 SW 15 Street,Suit #8138
Deerfield Beach,Florida 33442
United States
Toll Free: +1-855-465-4651 (USA-CANADA)
Tel: +1-386-310-3803
Email: sales@marketresearchstore.com
Website: http://www.marketresearchstore.com